Cancer incidence and mortality after treatment with folic acid and vitamin B12
- PMID: 19920236
- DOI: 10.1001/jama.2009.1622
Cancer incidence and mortality after treatment with folic acid and vitamin B12
Abstract
Context: Recently, concern has been raised about the safety of folic acid, particularly in relation to cancer risk.
Objective: To evaluate effects of treatment with B vitamins on cancer outcomes and all-cause mortality in 2 randomized controlled trials.
Design, setting, and participants: Combined analysis and extended follow-up of participants from 2 randomized, double-blind, placebo-controlled clinical trials (Norwegian Vitamin Trial and Western Norway B Vitamin Intervention Trial). A total of 6837 patients with ischemic heart disease were treated with B vitamins or placebo between 1998 and 2005, and were followed up through December 31, 2007.
Interventions: Oral treatment with folic acid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d) and vitamin B(6) (40 mg/d) (n = 1708); folic acid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d) (n = 1703); vitamin B(6) alone (40 mg/d) (n = 1705); or placebo (n = 1721).
Main outcome measures: Cancer incidence, cancer mortality, and all-cause mortality.
Results: During study treatment, median serum folate concentration increased more than 6-fold among participants given folic acid. After a median 39 months of treatment and an additional 38 months of posttrial observational follow-up, 341 participants (10.0%) who received folic acid plus vitamin B(12) vs 288 participants (8.4%) who did not receive such treatment were diagnosed with cancer (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.03-1.41; P = .02). A total of 136 (4.0%) who received folic acid plus vitamin B(12) vs 100 (2.9%) who did not receive such treatment died from cancer (HR, 1.38; 95% CI, 1.07-1.79; P = .01). A total of 548 patients (16.1%) who received folic acid plus vitamin B(12) vs 473 (13.8%) who did not receive such treatment died from any cause (HR, 1.18; 95% CI, 1.04-1.33; P = .01). Results were mainly driven by increased lung cancer incidence in participants who received folic acid plus vitamin B(12). Vitamin B(6) treatment was not associated with any significant effects.
Conclusion: Treatment with folic acid plus vitamin B(12) was associated with increased cancer outcomes and all-cause mortality in patients with ischemic heart disease in Norway, where there is no folic acid fortification of foods.
Trial registration: clinicaltrials.gov Identifier: NCT00671346.
Comment in
-
Assessing cancer prevention studies--a matter of time.JAMA. 2009 Nov 18;302(19):2152-3. doi: 10.1001/jama.2009.1691. JAMA. 2009. PMID: 19920243 Free PMC article. No abstract available.
Similar articles
-
Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial.JAMA. 2008 Aug 20;300(7):795-804. doi: 10.1001/jama.300.7.795. JAMA. 2008. PMID: 18714059 Clinical Trial.
-
Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.JAMA. 2007 Sep 12;298(10):1163-70. doi: 10.1001/jama.298.10.1163. JAMA. 2007. PMID: 17848650 Clinical Trial.
-
Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.JAMA. 2008 May 7;299(17):2027-36. doi: 10.1001/jama.299.17.2027. JAMA. 2008. PMID: 18460663 Free PMC article. Clinical Trial.
-
Efficacy of Vitamin B Supplementation on Cognition in Elderly Patients With Cognitive-Related Diseases.J Geriatr Psychiatry Neurol. 2017 Jan;30(1):50-59. doi: 10.1177/0891988716673466. Epub 2016 Oct 17. J Geriatr Psychiatry Neurol. 2017. PMID: 28248558 Review.
-
Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.Semin Thromb Hemost. 2000;26(3):341-8. doi: 10.1055/s-2000-8101. Semin Thromb Hemost. 2000. PMID: 11011852 Review.
Cited by
-
B Vitamins, Glucoronolactone and the Immune System: Bioavailability, Doses and Efficiency.Nutrients. 2023 Dec 20;16(1):24. doi: 10.3390/nu16010024. Nutrients. 2023. PMID: 38201854 Free PMC article. Review.
-
Metabolic Response of Triple-Negative Breast Cancer to Folate Restriction.Nutrients. 2021 May 13;13(5):1637. doi: 10.3390/nu13051637. Nutrients. 2021. PMID: 34068120 Free PMC article.
-
Prevention: B vitamins and CVD--failure to find a simple solution.Nat Rev Cardiol. 2010 Nov;7(11):608-9. doi: 10.1038/nrcardio.2010.138. Nat Rev Cardiol. 2010. PMID: 20975658 No abstract available.
-
Folic acid and human reproduction-ten important issues for clinicians.J Exp Clin Assist Reprod. 2011;8:2. Epub 2011 Aug 10. J Exp Clin Assist Reprod. 2011. PMID: 21991291 Free PMC article.
-
Homocysteine, cysteine, folate and vitamin B₁₂ status in type 2 diabetic patients with chronic kidney disease.J Nephrol. 2015 Oct;28(5):571-6. doi: 10.1007/s40620-014-0126-4. Epub 2014 Aug 6. J Nephrol. 2015. PMID: 25095762
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical